Arble, D M
Sandoval, D A
Turek, F W
Woods, S C
Seeley, R J
Article History
Received: 3 December 2014
Revised: 14 March 2015
Accepted: 4 April 2015
First Online: 14 April 2015
Competing interests
: DMA, FWT and SCW have no conflicts to declare. DAS receives funding from Ethicon Endo-Surgery, Novo Nordisk and Boehringer Ingelheim International. RJS receives funding from Ethicon Endo-Surgery, Ablaris Therapeutics, Inc., Novo Nordisk, Novartis, Angiochem, Eisai, Forest Pharmaceuticals, Givaudan, Zealand Pharmaceuticals and Boehringer Ingelheim International.